C-Rad AB (publ) (CRAD-B.ST)
SEK 29.9
(-0.17%)
SEK 29.9
(-0.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 48.9 Million SEK | 110.22% |
| 2022 | 27.5 Million SEK | -29.82% |
| 2021 | 45.71 Million SEK | 74.34% |
| 2020 | 26.15 Million SEK | 115.4% |
| 2019 | -4.87 Million SEK | 58.27% |
| 2018 | 3.35 Million SEK | 277.74% |
| 2017 | -5.47 Million SEK | 82.42% |
| 2016 | -24.46 Million SEK | -66.17% |
| 2015 | -14.82 Million SEK | -82.81% |
| 2014 | -7.82 Million SEK | 44.65% |
| 2013 | -14.17 Million SEK | -8.67% |
| 2012 | -13.44 Million SEK | 18.48% |
| 2011 | -16.48 Million SEK | -162.33% |
| 2010 | -6.28 Million SEK | 13.33% |
| 2009 | -7.25 Million SEK | 18.41% |
| 2008 | -8.88 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 20 Million SEK | -0.99% |
| 2024 Q3 | 19.6 Million SEK | -2.0% |
| 2024 Q1 | 12.6 Million SEK | -22.61% |
| 2023 Q1 | 8.6 Million SEK | -2.43% |
| 2023 FY | - SEK | 110.22% |
| 2023 Q4 | 31 Million SEK | 46.92% |
| 2023 Q2 | 9.7 Million SEK | 12.79% |
| 2023 Q3 | 21.1 Million SEK | 117.53% |
| 2022 Q3 | 17.1 Million SEK | 418.18% |
| 2022 Q1 | 2.8 Million SEK | -83.83% |
| 2022 Q2 | 3.3 Million SEK | 17.86% |
| 2022 FY | - SEK | -29.82% |
| 2022 Q4 | 8.81 Million SEK | -48.46% |
| 2021 Q3 | 11.2 Million SEK | 33.33% |
| 2021 FY | - SEK | 74.34% |
| 2021 Q2 | 8.4 Million SEK | -2.33% |
| 2021 Q1 | 8.6 Million SEK | -30.91% |
| 2021 Q4 | 17.31 Million SEK | 54.6% |
| 2020 FY | - SEK | 115.4% |
| 2020 Q3 | 7.7 Million SEK | 156.67% |
| 2020 Q2 | 3 Million SEK | 0.0% |
| 2020 Q1 | 3 Million SEK | 111.42% |
| 2020 Q4 | 12.44 Million SEK | 61.65% |
| 2019 Q1 | 3.5 Million SEK | -39.66% |
| 2019 Q2 | 1.8 Million SEK | -48.57% |
| 2019 Q3 | 4.3 Million SEK | 138.89% |
| 2019 FY | - SEK | 58.27% |
| 2019 Q4 | 1.41 Million SEK | -67.0% |
| 2018 Q4 | 5.8 Million SEK | 132.0% |
| 2018 Q2 | 3.1 Million SEK | 186.11% |
| 2018 FY | - SEK | 277.74% |
| 2018 Q1 | -3.6 Million SEK | -325.14% |
| 2018 Q3 | 2.5 Million SEK | -19.35% |
| 2017 Q3 | -300 Thousand SEK | 89.08% |
| 2017 Q1 | -4.04 Million SEK | -25.39% |
| 2017 FY | - SEK | 82.42% |
| 2017 Q4 | 1.59 Million SEK | 633.0% |
| 2017 Q2 | -2.74 Million SEK | 32.15% |
| 2016 Q3 | -6.44 Million SEK | 22.31% |
| 2016 Q4 | -3.22 Million SEK | 49.91% |
| 2016 FY | - SEK | -66.17% |
| 2016 Q1 | -6.59 Million SEK | -59.72% |
| 2016 Q2 | -8.29 Million SEK | -25.78% |
| 2015 Q1 | -454.19 Thousand SEK | 82.65% |
| 2015 FY | - SEK | -82.81% |
| 2015 Q4 | -4.12 Million SEK | 22.31% |
| 2015 Q3 | -5.31 Million SEK | -8.83% |
| 2015 Q2 | -4.88 Million SEK | -975.01% |
| 2014 Q1 | -798.46 Thousand SEK | 48.83% |
| 2014 Q3 | -1.54 Million SEK | 49.68% |
| 2014 FY | - SEK | 44.65% |
| 2014 Q4 | -2.61 Million SEK | -69.05% |
| 2014 Q2 | -3.07 Million SEK | -285.31% |
| 2013 FY | - SEK | -8.67% |
| 2013 Q1 | -4.36 Million SEK | -616.93% |
| 2013 Q2 | -8.38 Million SEK | -92.11% |
| 2013 Q3 | -305 Thousand SEK | 96.36% |
| 2013 Q4 | -1.56 Million SEK | -411.65% |
| 2012 Q1 | -5.85 Million SEK | -22.83% |
| 2012 FY | - SEK | 18.48% |
| 2012 Q4 | 843.82 Thousand SEK | 120.01% |
| 2012 Q3 | -4.21 Million SEK | 1.31% |
| 2012 Q2 | -4.27 Million SEK | 27.02% |
| 2011 Q1 | -3.16 Million SEK | -9.33% |
| 2011 Q4 | -4.76 Million SEK | -148.83% |
| 2011 Q2 | -6.63 Million SEK | -109.5% |
| 2011 Q3 | -1.91 Million SEK | 71.12% |
| 2011 FY | - SEK | -162.33% |
| 2010 Q2 | -2.55 Million SEK | -236.45% |
| 2010 Q3 | -72 Thousand SEK | 97.18% |
| 2010 Q1 | -760 Thousand SEK | -97.6% |
| 2010 FY | - SEK | 13.33% |
| 2010 Q4 | -2.89 Million SEK | -3923.24% |
| 2009 Q3 | -2.83 Million SEK | -25.37% |
| 2009 Q2 | -2.25 Million SEK | -27.2% |
| 2009 Q1 | -1.77 Million SEK | 45.72% |
| 2009 FY | - SEK | 18.41% |
| 2009 Q4 | -384.61 Thousand SEK | 86.42% |
| 2008 FY | - SEK | 0.0% |
| 2008 Q2 | -1.39 Million SEK | 34.87% |
| 2008 Q1 | -2.14 Million SEK | 0.0% |
| 2008 Q3 | -2.19 Million SEK | -57.06% |
| 2008 Q4 | -3.27 Million SEK | -49.35% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 163.411% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 88.127% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 88.127% |
| Arcoma AB | 6.24 Million SEK | -682.714% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 154.349% |
| BICO Group AB (publ) | 322.3 Million SEK | 84.827% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 25.879% |
| CellaVision AB (publ) | 207.24 Million SEK | 76.403% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 171.491% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 275.013% |
| Duearity AB (publ) | -24.77 Million SEK | 297.361% |
| Dignitana AB (publ) | -264 Thousand SEK | 18624.242% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 155.763% |
| Getinge AB (publ) | 5.92 Billion SEK | 99.175% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 172.72% |
| Iconovo AB (publ) | -35.33 Million SEK | 238.399% |
| Integrum AB (publ) | 8.76 Million SEK | -458.167% |
| Luxbright AB (publ) | -23.86 Million SEK | 304.904% |
| Mentice AB (publ) | 28.87 Million SEK | -69.376% |
| OssDsign AB (publ) | -122.02 Million SEK | 140.078% |
| Paxman AB (publ) | 31.22 Million SEK | -56.598% |
| Promimic AB (publ) | -3.68 Million SEK | 1427.471% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 132.493% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 194.356% |
| ScandiDos AB (publ) | -13.35 Million SEK | 466.158% |
| Sectra AB (publ) | 615.06 Million SEK | 92.049% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 194.639% |
| Senzime AB (publ) | -118.82 Million SEK | 141.157% |
| SpectraCure AB (publ) | -20.96 Million SEK | 333.22% |
| Stille AB | 56.04 Million SEK | 12.735% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 101.535% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 61.363% |